Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 38 | SFEBES2015 | Next issue

Society for Endocrinology BES 2015

Edinburgh, UK
02 Nov 2015 - 04 Nov 2015

Card image cap
2-4 November 2015, Edinburgh, UK Further information

Symposia

The rise and rise of the FGFs in endocrinology

ea0038s7.2 | The rise and rise of the FGFs in endocrinology | SFEBES2015

FGF21: starvation hormone to a clinical drug?

Kharitonenkov Alexei , Agrawal Archita , Li Pengyun , DiMarchi Richard , Perez-Tlive Diego

Fibroblast growth factor 21 (FGF21) is an emerging regulator of energy homeostasis and a novel target for the development of therapies to treat diabetes, cardiovascular disease, and obesity. FGF21 was discovered in an in vitro high throughput screen. It was later shown to have impressive metabolic pharmacology including glucose, lipid, and body weight lowering effects in a variety of animal models, including non-human primates. When tested clinically an FGF21-based an...

ea0038s7.3 | The rise and rise of the FGFs in endocrinology | SFEBES2015

The increasing understanding of FGF23 in pathogenesis and treatment of diverse endocrine disease

Peacock Munro

Phosphate is an essential ion for mineralization of bone. Hypophosphatemia leads to rickets and osteomalacia whereas hyperphosphatemia promotes ectopic calcification in soft tissues. FGF23 is a polypeptide hormone secreted by bone that regulates serum phosphate concentration. It acts on kidney to decrease phosphate reabsorption, and 1,25-dihydroxy vitamin D secretion which in turn reduces phosphorus absorption by the gut. Its action on the renal tubule appears to require PTH a...